by Dom Partridge | Oct 8, 2026 | Industry insights
Written by Louis Barwell September was a month in which health technology assessment (HTA) policy and HTA decisions were closely linked. In the UK, the pricing agreement with the US came under parliamentary scrutiny not long after the agreement was formalised,...
by Josee Leach | Sep 21, 2026 | Industry insights
The type of model used in economic evaluations of healthcare interventions is critical to ensuring the features of the health condition and treatment effects are appropriately captured whilst minimising uncertainty. For example, Partitioned survival models...
by Josee Leach | Sep 15, 2026 | Industry insights
A phase two readout lands. Weeks later, in your first regulatory meeting, you discover the new joint clinical assessment process requires comparator data you don’t have. The trial has already finished enrolling. There’s no going back to fix the design. ...
by Dom Partridge | Sep 9, 2026 | Industry insights
Written by Benjamin Clark, Kiera Lander, and Toby Hobbs August brought a busy month for health technology assessment (HTA), with developments spanning the EU, UK, and Ireland; including a new tool to help health technology developers navigate Joint Clinical...
by Dom Partridge | Jun 2, 2026 | Industry insights
Written by Paloma Charlesworth Introduction From the 17th–20th May 2026, the Professional Society for Health Economics and Outcomes Research (ISPOR) annual conference took place in Philadelphia, convening stakeholders from across the health economics and outcomes...
by Dom Partridge | Apr 30, 2026 | Industry insights
Written by Kiera Lander & Oliver Burn 1 – A NICE modular update: adopting the EQ‑5D‑5L UK value set What is changing (methods update) The National Institute for Health and Care Excellence (NICE) is consulting on a modular update to adopt the EQ‑5D‑5L dataset...
